Institut National de la Santé et de la Recherche Médicale (INSERM) U848, F-94805 Villejuif, France.
J Exp Med. 2011 Aug 29;208(9):1823-34. doi: 10.1084/jem.20101805. Epub 2011 Aug 22.
Extracellular adenosine triphosphate (ATP) can activate purinergic receptors of the plasma membrane and modulate multiple cellular functions. We report that ATP is released from HIV-1 target cells through pannexin-1 channels upon interaction between the HIV-1 envelope protein and specific target cell receptors. Extracellular ATP then acts on purinergic receptors, including P2Y2, to activate proline-rich tyrosine kinase 2 (Pyk2) kinase and transient plasma membrane depolarization, which in turn stimulate fusion between Env-expressing membranes and membranes containing CD4 plus appropriate chemokine co-receptors. Inhibition of any of the constituents of this cascade (pannexin-1, ATP, P2Y2, and Pyk2) impairs the replication of HIV-1 mutant viruses that are resistant to conventional antiretroviral agents. Altogether, our results reveal a novel signaling pathway involved in the early steps of HIV-1 infection that may be targeted with new therapeutic approaches.
细胞外三磷酸腺苷(ATP)可激活质膜上的嘌呤能受体,调节多种细胞功能。我们报告称,当 HIV-1 包膜蛋白与特定靶细胞受体相互作用时,ATP 通过连接蛋白-1 通道从 HIV-1 靶细胞中释放出来。然后,细胞外 ATP 作用于嘌呤能受体,包括 P2Y2,激活富含脯氨酸的酪氨酸激酶 2(Pyk2)激酶并导致瞬时质膜去极化,进而刺激表达Env 的膜与包含 CD4 和适当趋化因子共受体的膜之间融合。抑制该级联反应的任何成分(连接蛋白-1、ATP、P2Y2 和 Pyk2)都会损害对传统抗逆转录病毒药物有抗性的 HIV-1 突变病毒的复制。总之,我们的研究结果揭示了 HIV-1 感染早期步骤中涉及的一种新的信号通路,该通路可能成为新的治疗方法的靶点。